Quantum Financial Advisors LLC Raises Stake in Johnson & Johnson (NYSE:JNJ)

Quantum Financial Advisors LLC boosted its position in Johnson & Johnson (NYSE:JNJ) by 153.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,601 shares of the company’s stock after buying an additional 3,387 shares during the quarter. Quantum Financial Advisors LLC’s holdings in Johnson & Johnson were worth $929,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Founders Capital Management boosted its stake in shares of Johnson & Johnson by 0.3% during the first quarter. Founders Capital Management now owns 34,950 shares of the company’s stock valued at $5,796,000 after purchasing an additional 101 shares during the period. Aletheian Wealth Advisors LLC boosted its stake in shares of Johnson & Johnson by 63.2% during the first quarter. Aletheian Wealth Advisors LLC now owns 2,511 shares of the company’s stock valued at $416,000 after purchasing an additional 972 shares during the period. Bowman & Co S.C. boosted its stake in shares of Johnson & Johnson by 17.9% during the first quarter. Bowman & Co S.C. now owns 11,135 shares of the company’s stock valued at $1,846,000 after purchasing an additional 1,689 shares during the period. Allied Investment Advisors LLC raised its holdings in shares of Johnson & Johnson by 10.3% during the first quarter. Allied Investment Advisors LLC now owns 68,905 shares of the company’s stock valued at $11,427,000 after acquiring an additional 6,441 shares in the last quarter. Finally, Fifth Third Wealth Advisors LLC raised its holdings in shares of Johnson & Johnson by 23.4% during the first quarter. Fifth Third Wealth Advisors LLC now owns 26,613 shares of the company’s stock valued at $4,413,000 after acquiring an additional 5,038 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.9%

Shares of NYSE:JNJ opened at $154.99 on Friday. The stock has a market capitalization of $372.92 billion, a price-to-earnings ratio of 23.31, a PEG ratio of 2.56 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The stock’s 50-day simple moving average is $154.31 and its two-hundred day simple moving average is $153.65. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $21.89 billion for the quarter, compared to analysts’ expectations of $21.65 billion. Analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be given a dividend of $1.30 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.36%. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson’s payout ratio is presently 57.84%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on JNJ shares. Benchmark upgraded Johnson & Johnson to a “strong-buy” rating in a report on Thursday, April 24th. Leerink Partners downgraded Johnson & Johnson from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Raymond James decreased their price objective on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a report on Monday, April 14th. Morgan Stanley increased their price objective on Johnson & Johnson from $164.00 to $169.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 16th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, April 16th. Eleven investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.